FINWIRES · TerminalLIVE
FINWIRES

奥本海默公司称，尽管Passage Bio在FDA遭遇挫折，但仍被低估。

-- 奥本海默周二在一份报告中指出，鉴于PBFT02的独特优势，Passage Bio (PASG) 的股价被“低估”，而美国食品药品监督管理局 (FDA) 的反馈意见延长了其获批之路。 分析师表示，该公司周一公布了其upliFT-D研究的数据以及FDA的反馈意见。此次更新喜忧参半。积极的一面是，临床数据表明，PBFT02可能仍然值得继续研发，尤其是在病情较轻的患者中。然而，FDA的反馈意见却是一个挫折。FDA指出，单臂关键性研究不足以获得批准。 分析师表示，他们看到了前粒蛋白靶点在某些神经退行性疾病中的应用前景。尽管该领域的其他项目在额颞叶痴呆 (FTD) 的治疗中难以展现出明显的疗效，但PBFT02凭借其作用机制、给药方式以及目前已获得的数据脱颖而出。作为一种一次性非手术疗法，如果获得批准，它可能具有强大的商业优势。 分析师补充道：“鉴于PBFT02相对于其他FTD在研药物的优势，我们认为Passage Bio的估值偏低，而FTD目前仍是高度未被满足的医疗需求领域。” 奥本海默将Passage Bio的目标股价从30美元下调至15美元，同时维持其“跑赢大盘”的评级。

Price: $5.96, Change: $-0.30, Percent Change: -4.72%

Related Articles

Asia

Bank of Queensland Posts Lower Fiscal H1 Cash Earnings, Higher Revenue

Bank of Queensland (ASX:BOQ) reported Wednesday fiscal first-half cash earnings of AU$0.253 per share, down from AU$0.264 a year earlier.Analysts polled by FactSet expected earnings of AU$0.26.Revenue from ordinary activities for the six months ended Feb. 28 was AU$835 million, compared with AU$802 million a year earlier.Analysts surveyed by FactSet expected AU$839 million.The company has maintained its common equity tier 1 management target range at 10.25% to 10.75%, along with an unchanged dividend payout ratio target of 60% to 75% of cash earnings, while also keeping its cost guidance steady and continuing to expect cost growth from 2025 to 2026 to remain below the rate of inflation.The board declared an interim dividend of AU$0.20 per share, up from AU$0.18 a year earlier, payable May 27 to shareholders on record as of May 5.

$ASX:BOQ
Asia

Carnaby Resources Continues to Be Undervalued Relative to Peers, Euroz Hartleys Says

Carnaby Resources (ASX:CNB) continues to be undervalued relative to its peers and given its production potential, Euroz Hartleys said in a Tuesday note, adding that the market may have missed a near-term production opportunity.The company has commenced a roughly 3,000 meters reverse circulation drilling program at its Greater Duchess copper gold project in Queensland, targeting extensions of high-priority mineralization at the Trekelano deposit.In addition, more assay results from a recently completed diamond drilling program are also pending, providing near-term news flow alongside the current drilling program, the equity research firm said.Leveraging its binding tolling and offtake deals with Glencore provides a low capital pathway to first production for Carnaby, and the first three years of production on Euroz Hartleys' modeling should come from lower-risk open pit reserves in the Trekelano, Mt Hope and Lady Fanny operations, it said.The equity research firm maintain a speculative buy recommendation on the stock with a price target of AU$0.96.

$ASX:CNB
Asia

South32 Posts 1% Rise in Year-to-March Alumina Production

South32 (ASX:S32) reported a 1% increase in alumina production year-to-date to March, helped by record production in its Brazil Alumina segment, according to a Wednesday filing with the Australian bourse.Aluminium production was mostly flat during the period, as its Hillside Aluminium smelter continued to evaluate its maximum technical capacity.Sierra Gorda, a Chile-based copper mine in which South32 holds a 45% stake, delivered a record quarterly distribution of $135 million to the company.South32 said its annual production guidance remained on track for all operations, apart from Australia Manganese, where the fiscal 2026 production outlook was cut by 6% to 3,000 kilo wet metric tonnes due to elevated site water levels and heavy rainfall following Tropical Cyclone Narelle.

$ASX:S32